Haloperidol Prophylaxis in Cardiac Surgery for Patients at Risk for Delirium
NCT ID: NCT01862302
Last Updated: 2016-09-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
25 participants
INTERVENTIONAL
2013-08-31
2016-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Preventing Post-Operative Delirium in Patients Undergoing a Pneumonectomy, Esophagectomy or Thoracotomy
NCT02213900
Post-operative Haloperidol Versus Placebo for Prevention of Post-operative Delirium After Acute Hip Surgery
NCT00250237
Pharmacological Management of Delirium
NCT00842608
The Delirium-CS Canada Study
NCT02206880
Post-surgical Delirium in Patients Undergoing Open Heart Surgery.
NCT03806413
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Haloperidol
Haloperidol 1mg the night before and 1mg the morning of surgery; OR Haloperidol 2mg the morning of surgery
Haloperidol
1mg the night before and 1mg the morning of surgery; OR Haloperidol 2mg the morning of surgery
Placebo
1 dose the night before and 1 dose the morning of surgery; OR 2 doses the morning of surgery
Placebo
1 dose the night before and 1 dose the morning of surgery; OR 2 doses the morning of surgery
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Haloperidol
1mg the night before and 1mg the morning of surgery; OR Haloperidol 2mg the morning of surgery
Placebo
1 dose the night before and 1 dose the morning of surgery; OR 2 doses the morning of surgery
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* TIA/Stroke;
* Euroscore greater than or equal to 5;
* abnormal clock draw.
Exclusion Criteria
* on any antipsychotic medications pre-op,
* active delirium,
* emergent surgery,
* Haloperidol allergy,
* schizophrenia,
* prolonged QTc.
60 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
McMaster University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Andre Lamy
Dr Andre Lamy, MD, FRCSC, MHSc, Cardiac Surgeon
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Andre Lamy, MD
Role: PRINCIPAL_INVESTIGATOR
McMaster University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hamilton General Site
Hamilton, Ontario, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HALPCARD-2013
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.